Home All NewsBusiness NewsOpko Health shares rise on Merck deal for experimental Epstein-Barr vaccine

Opko Health shares rise on Merck deal for experimental Epstein-Barr vaccine

by Reuters

(Reuters) -Opko Health Inc said on Wednesday it signed a deal with Merck & Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine.

Shares of Opko rose as much as 24%, before paring gains to trade 9.4% higher at $1.16.

Merck will take over the clinical and regulatory activities related to the vaccine, as well its commercialization once the drugmaker files a joint application with Opko unit ModeX Therapeutics to test it in humans, the company said.

Opko will receive an upfront payment of $50 million and is eligible for milestone payments of up to $872.5 million, plus royalties, on global sales.

There is currently no vaccine for the Epstein-Barr virus, which is the leading cause of mononucleosis, or mono, commonly called the “kissing disease”.

(Reporting by Aditya Samal in Bengaluru; Editing by Pooja Desai)

tagreuters.com2023binary_LYNXMPEJ270HD-BASEIMAGE

You may also like

You can't access this website

Shore News Network provides free news to users. No paywalls. No subscriptions. Please support us by disabling ad blocker or using a different browser and trying again.